New low-dose LABA/corticosteroid inhaler for asthma

A lower-dose metered-dose inhaler has been added to the Symbicort range.

Symbicort metered-dose inhaler (budesonide/formoterol) is now available in a 100/3 presentation. | AstraZeneca
Symbicort metered-dose inhaler (budesonide/formoterol) is now available in a 100/3 presentation. | AstraZeneca

The Symbicort 100/3 pressurised metered-dose inhaler delivers 80 micrograms of budesonide and 2.25 micrograms of formoterol fumarate dihydrate per puff, from a metered dose of 100 micrograms and 3 micrograms respectively.

Symbicort 100/3 is indicated in adults and adolescents from 12 years for the regular treatment of asthma where use of a combination (inhaled corticosteroid and long-acting ß2 agonist) is appropriate, including:

  • in patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short-acting ß2 agonists, and
  • in patients already adequately controlled on both inhaled corticosteroids and long-acting ß2 agonists.

Symbicort 100/3 can be used for both maintenance and maintenance/reliever therapy.

The existing 200/6 Symbicort pMDI is licensed for use only in patients with COPD. Symbicort 100/3 pMDI is not approved for COPD.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in